Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, often driven by autoantibodies.
• FcRn antagonists like efgartigimod and rozanolixizumab reduce immunoglobulin G (IgG) levels and alleviate generalized MG symptoms.

Purpose of the Study:

• To evaluate the efficacy and safety of batoclimab, a monoclonal IgG1 antibody, in adult patients with generalized MG.

Main Methods:

• A multicenter, randomized clinical trial involving 132 adult patients with generalized MG in China.
• Patients received either batoclimab (680 mg subcutaneously weekly for 6 weeks) or placebo, alongside standard care.
• The primary outcome was sustained improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score.

Main Results:

• Batoclimab significantly increased the rate of sustained MG-ADL improvement compared to placebo (58.2% vs 31.3%, P=.001).
• Improvements were observed early, with a greater mean reduction in MG-ADL scores in the batoclimab group.
• Treatment-related adverse events were higher with batoclimab (70.1%) but severe events were lower (3.0%) compared to placebo (36.9% and 7.7%, respectively).

Conclusions:

• Batoclimab effectively improved sustained daily functioning in generalized MG patients.
• Its clinical effects and IgG reduction are comparable to other FcRn antagonists.
• Further large-scale studies are warranted to fully elucidate batoclimab's safety profile.